News | Thrombectomy Devices | February 05, 2019

Delayed Clot Removal Still Improves Quality of Life Post-Stroke

Patients surveyed in DEFUSE 3 trial had better quality of life with thrombectomy up to 24 hours after symptom onset compared to medical therapy alone

Delayed Clot Removal Still Improves Quality of Life Post-Stroke

February 5, 2019  — Stroke survivors have better quality of life three months after their stroke if the clot that caused the stroke was mechanically removed even hours beyond the ideal treatment window compared to those treated with drugs alone. This preliminary research will be presented, Feb. 6-8 in Honolulu at the American Stroke Association’s International Stroke Conference 2019.

Researchers have found that mechanically removing a clot in stroke patients, called endovascular therapy, can limit disability from stroke. While the therapy is most effective when performed within six hours of symptom onset, it can also reduce functional deficits in patients up to 24 hours after stroke symptoms start.

In the DEFUSE 3 trial, Stanford University School of Medicine researchers studied whether stroke survivors who were treated with endovascular therapy in the late six-to-16-hour time window might have better quality of life than people treated only with standard drug therapy. They examined a subset of ischemic stroke patients who had salvageable tissue visible on brain imaging.

Researchers surveyed patients 90 days after stroke about their mobility, ability to participate in social activities, cognitive (or thinking) function and depression.

Based on results from 136 patients who completed all or some of the surveys, people treated with endovascular therapy had superior quality-of-life results in all four domains, compared to those who had medical therapy alone.

“In addition to improved functional outcomes, endovascular therapy six to 16 hours after onset preserves mental health and social capabilities critical to patients’ quality of life,” researchers said.

For more information: www.professional.heart.org

Related Content

News | Thrombectomy Devices

January 10, 2022 – Akura Medical Inc., a Shifamed portfolio company, announced the closing of its $25 million Series A1 ...

Home January 10, 2022
Home
News | Thrombectomy Devices

November 12, 2021 — Penumbra Inc. announced that the CHEETAH clinical study of its Indigo System CAT RX Catheter ...

Home November 12, 2021
Home
News | Thrombectomy Devices

January 8, 2021 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Inari Medical Inc ...

Home January 08, 2021
Home
News | Thrombectomy Devices

September 25, 2020 — Philips Healthcare launched its QuickClear mechanical thrombectomy system. The compact, single-use ...

Home September 25, 2020
Home
Technology | Thrombectomy Devices

July 25, 2019 — Penumbra announced U.S. commercial availability of the Penumbra System’s most advanced technology, the ...

Home July 25, 2019
Home
News | Thrombectomy Devices

February 12, 2019 — A study presented at the 2018 annual meeting of the Cardiovascular and Interventional Radiology ...

Home February 12, 2019
Home
Feature | Thrombectomy Devices | Dave Fornell, Editor

Catheter-based blood clot removal a decade ago was a standard of care for acute coronary revascularization, but declined ...

Home January 22, 2019
Home
News | Thrombectomy Devices

January 16, 2019 — Cerenovus, of Johnson & Johnson Medical Devices Companies, recently launched the EXCELLENT Registry ...

Home January 16, 2019
Home
News | Thrombectomy Devices

November 21, 2018 — BTG plc announced the first Ekos CU 4.0 units have been shipped from BTG’s facility in Bothell, Wash ...

Home November 21, 2018
Home
News | Thrombectomy Devices

May 21, 2018 — Medtronic and the U.S. Food and Drug Administration (FDA) announced a Class I Urgent Medical Device ...

Home May 21, 2018
Home
Subscribe Now